Sponsor:
BeiGene
Code:
NCT05100862
Conditions
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Zanubrutinib
Rituximab
Lenalidomide
Obinutuzumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by BeiGene on 2025-04-13.